The benefit of radiosurgery for ARUBA-eligible arteriovenous malformations: a practical analysis over an appropriate follow-up period

• Published in: Journal of neurosurgery Vol. 128; no. 6; pp. 1850 - 1854
• Main Authors: Tonetti, Daniel A, Gross, Bradley A, Atcheson, Kyle M, Jankowitz, Brian T, Kano, Hideyuki, Monaco, Edward A, Niranjan, Ajay, Flickinger, John C, Lunsford, L Dade
• Format: Journal Article
• Language: English
• Published: United States 01-06-2018
• Subjects: arteriovenous malformation; SRS; AVM = arteriovenous malformation; AVM; ARUBA; SRS = stereotactic radiosurgery; stroke; vascular disorders; ARUBA = A Randomized Trial of Unruptured Brain Arteriovenous Malformations; hemorrhage; stereotactic radiosurgery
• ISSN: 0022-3085; 1933-0693
• DOI: 10.3171/2017.1.jns162962

OBJECTIVE The authors of this study found that, given the latency period required for arteriovenous malformation (AVM) obliteration after stereotactic radiosurgery (SRS), a study with limited follow-up cannot assess the benefit of SRS for unruptured AVMs. METHODS The authors reviewed their institutional experience with "ARUBA (A Randomized Trial of Unruptured Brain Arteriovenous Malformations)-eligible" AVMs treated with SRS between 1987 and 2016, with the primary outcome defined as stroke (ischemic or hemorrhagic) or death (AVM related or AVM unrelated). Patients with at least 3 years of follow-up in addition to those who experienced stroke or died during the latency period were included. Secondary outcome measures included obliteration rates, patients with new seizure disorders, and those with new focal deficits without stroke. RESULTS Of 233 patients included in this study, 32 had a stroke or died after SRS over the mean 8.4-year follow-up (14%). Utilizing the 10% stroke or death rate at a mean 2.8-year follow-up for untreated AVMs in ARUBA, the rate in the authors' study is significantly lower than that anticipated at the 8.4-year follow-up for an untreated cohort (14% vs 30%, p = 0.0003). Notwithstanding obliteration, in this study, annualized rates of hemorrhage and stroke or death after 3 years following SRS were 0.4% and 0.8%, respectively. The overall obliteration rate was 72%; new seizure disorders, temporary new focal deficits without stroke, and permanent new focal deficits without stroke occurred in 2% of patients each. CONCLUSIONS After a sensible follow-up period exceeding the latency period, there is a lower rate of stroke/death for patients with treated, unruptured AVMs with SRS than for patients with untreated AVMs.